Another Canadian cannabis company has fallen victim to the weak market, with Zenabis Global (TSX:ZENA) announcing a significant cut to its workforce. 

On Wednesday (March 11), the Vancouver-based licensed producer (LP), which has operations across Canada, confirmed it has let go of 22 percent of its overall workforce.

Shares of the company quickly fell in Thursday’s (March 12) trading session following the news. Zenabis opened at C$0.06, but midway through the trading day the firm had seen a drop of 21.43 percent in value, resulting in a price per share of C$0.05.

In a statement, Zenabis CEO Kevin Coft said the firm is aiming to become cash flow positive in 2020 through this operational efficiency measure.

Given the current climate for cannabis sales in Canada, the company does not plan to expand or create more growing options for itself; it believes its current capacity is enough to meet demand.

Although Zenabis expressed excitement about the expected growth Canadian cannabis sales could see from an increase in the availability of edible and infused products, the company told investors it anticipates that sales from the unregulated cannabis market will continue to impact wholesale prices, as well as the legal cannabis market’s expansion.

Zenabis joins a growing list of marijuana operations in Canada that have had to face cuts amid the financial realities of the capital markets.

Most recently, Canopy Growth (NYSE:CGC,TSX:WEED) announced plans to shut down operations at two facilities located in Aldergrove and Delta, BC. It also terminated approximately 500 positions.

In February, Tilray (NASDAQ:TLRY) confirmed it would let go of about 10 percent of its workforce. Similar reductions have been seen at Aurora Cannabis (NYSE:ACB,TSX:ACB) and The Supreme Cannabis Company (TSX:FIRE,OTCQX:SPRWF).

Charles Taerk, CEO of Faircourt Asset Management, a sub-advisor to Ninepoint Partners’ cannabis-focused fund, told the Investing News Network (INN) that the cuts from Canopy in particular were no surprise and will actually be beneficial to the firm in the long term.

“I think that there are many companies that are finding it difficult to operate in this capital-constrained environment,” he told INN.

Zenabis became part of another larger trend in the Canadian cannabis market when its CEO suddenly departed. In December, the firm notified investors that Andrew Grieve was out as its executive leader.

“Most of these cuts for costs will actually turn out to be positive and help the lifespan of these companies,” Nawan Butt, a portfolio manager at Purpose Investments, previously told INN in a wide-ranging conversation about the cannabis market.

Zenabis was also in the news last year when it faced pressure in the markets as it attempted to defend a rights offering plan.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less